Jodie Morrison

Jodie Morrison is an accomplished executive and board member with experience from start up through mid-size public biotech and pharmaceutical companies. She currently serves as CEO of Q32 Bio (QTTB), a publicly traded clinical stage biotech company, which she joined from her role as a Venture Partner at the founding investor Atlas Venture. Her prior operating roles include CEO of Cadent Therapeutics (acquired by Novartis in 2021), CEO at Keryx Biopharmaceuticals, Inc. (successful public/public MOE with Akebia Therapeutics), COO at Syntimmune, CEO of eGenesis and CEO of Tokai Pharmaceuticals, Inc. Other prior roles include COO and VP/Head of Clinical and Program Operations at Tokai and various roles in clinical operations and medical affairs at Dyax Corporation, Curis, Inc., and Diacrin, Inc. Ms. Morrison currently serves as a board member at Verve (VERV). She previously held public board roles at Aileron (ALRN), Ribon (private, chairman), Keryx (KERX), prior to CEO role, Akebia (AKBA) and Novus (NVUS). She also serves as a board member at Life Science Cares and on the key advisory board for Harvard Business School’s Blavatnik Fellowship in Life Science Entrepreneurship. Jodie has been awarded the Boston Business Journal’s “Power 50” and “Women to Watch” awards and WEST’s “Making a Difference” award. Ms. Morrison received her business training through the GBEP program at the MIT Sloan School of Management, her clinical research certification from Boston University School of Medicine and her B.A. in neuroscience from Mount Holyoke College.